Literature DB >> 32601072

A Structure-Function-Inhibition Analysis of the Pseudomonas aeruginosa Type III Secretion Needle Protein PscF.

Donald T Moir1, Nicholas O Bowlin2, Bryan J Berube3,4, Jaden Yabut2, Debra M Mills2, Giang T Nguyen5, Zachary D Aron2, John D Williams2, Joan Mecsas6, Alan R Hauser3, Terry L Bowlin2.   

Abstract

The Pseudomonas aeruginosa type III secretion system (T3SS) needle comprised of multiple PscF subunits is essential for the translocation of effector toxins into human cells, facilitating the establishment and dissemination of infection. Mutations in the pscF gene provide resistance to the phenoxyacetamide (PhA) series of T3SS inhibitory chemical probes. To better understand PscF functions and interactions with PhA, alleles of pscF with 71 single mutations altering 49 of the 85 residues of the encoded protein were evaluated for their effects on T3SS phenotypes. Of these, 37% eliminated and 63% maintained secretion, with representatives of both evenly distributed across the entire protein. Mutations in 14 codons conferred a degree of PhA resistance without eliminating secretion, and all but one were in the alpha-helical C-terminal 25% of PscF. PhA-resistant mutants exhibited no cross-resistance to two T3SS inhibitors with different chemical scaffolds. Two mutations caused constitutive T3SS secretion. The pscF allele at its native locus, whether wild type (WT), constitutive, or PhA resistant, was dominant over other pscF alleles expressed from nonnative loci and promoters, but mixed phenotypes were observed in chromosomal ΔpscF strains with both WT and mutant alleles at nonnative loci. Some PhA-resistant mutants exhibited reduced translocation efficiency that was improved in a PhA dose-dependent manner, suggesting that PhA can bind to those resistant needles. In summary, these results are consistent with a direct interaction between PhA inhibitors and the T3SS needle, suggest a mechanism of blocking conformational changes, and demonstrate that PscF affects T3SS regulation, as well as carrying out secretion and translocation.IMPORTANCE P. aeruginosa effector toxin translocation into host innate immune cells is critical for the establishment and dissemination of P. aeruginosa infections. The medical need for new anti-P. aeruginosa agents is evident by the fact that P. aeruginosa ventilator-associated pneumonia is associated with a high mortality rate (40 to 69%) and recurs in >30% of patients, even with standard-of-care antibiotic therapy. The results described here confirm roles for the PscF needle in T3SS secretion and translocation and suggest that it affects regulation, possibly by interaction with T3SS regulatory proteins. The results also support a model of direct interaction of the needle with PhA and suggest that, with further development, members of the PhA series may prove useful as drugs for P. aeruginosa infection.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  P. aeruginosazzm321990; phenoxyacetamides; translocation; type III needle protein; type III secretion

Mesh:

Substances:

Year:  2020        PMID: 32601072      PMCID: PMC7925083          DOI: 10.1128/JB.00055-20

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  65 in total

1.  The PscE-PscF-PscG complex controls type III secretion needle biogenesis in Pseudomonas aeruginosa.

Authors:  Manuelle Quinaud; Jacqueline Chabert; Eric Faudry; Emmanuelle Neumann; David Lemaire; Alexandrine Pastor; Sylvie Elsen; Andréa Dessen; Ina Attree
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

2.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).

Authors:  John D Williams; Matthew C Torhan; Venugopal R Neelagiri; Carson Brown; Nicholas O Bowlin; Ming Di; Courtney T McCarthy; Daniel Aiello; Norton P Peet; Terry L Bowlin; Donald T Moir
Journal:  Bioorg Med Chem       Date:  2015-01-13       Impact factor: 3.641

4.  A mutant with aberrant extracellular LcrV-YscF interactions fails to form pores and translocate Yop effector proteins but retains the ability to trigger Yop secretion in response to host cell contact.

Authors:  Dana E Harmon; Julia L Murphy; Alison J Davis; Joan Mecsas
Journal:  J Bacteriol       Date:  2013-03-08       Impact factor: 3.490

Review 5.  Targeting virulence: can we make evolution-proof drugs?

Authors:  Richard C Allen; Roman Popat; Stephen P Diggle; Sam P Brown
Journal:  Nat Rev Microbiol       Date:  2014-04       Impact factor: 60.633

6.  Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.

Authors:  Anna M Kauppi; Roland Nordfelth; Hanna Uvell; Hans Wolf-Watz; Mikael Elofsson
Journal:  Chem Biol       Date:  2003-03

7.  Development and application of a cellular, gain-of-signal, bioluminescent reporter screen for inhibitors of type II secretion in Pseudomonas aeruginosa and Burkholderia pseudomallei.

Authors:  Donald T Moir; Ming Di; Erica Wong; Richard A Moore; Herbert P Schweizer; Donald E Woods; Terry L Bowlin
Journal:  J Biomol Screen       Date:  2011-05-20

8.  Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy.

Authors:  Jose Garnacho-Montero; Marcio Sa-Borges; Jordi Sole-Violan; Fernando Barcenilla; Ana Escoresca-Ortega; Miriam Ochoa; Aurelio Cayuela; Jordi Rello
Journal:  Crit Care Med       Date:  2007-08       Impact factor: 7.598

9.  Ventilator-associated pneumonia due to Pseudomonas aeruginosa.

Authors:  S Crouch Brewer; R G Wunderink; C B Jones; K V Leeper
Journal:  Chest       Date:  1996-04       Impact factor: 9.410

10.  Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure.

Authors:  Benjamin Planquette; Jean-Francois Timsit; Benoit Y Misset; Carole Schwebel; Elie Azoulay; Christophe Adrie; Aurélien Vesin; Samir Jamali; Jean-Ralph Zahar; Bernard Allaouchiche; Bertrand Souweine; Michael Darmon; Anne-Sylvie Dumenil; Dany Goldgran-Toledano; Bruno H Mourvillier; Jean-Pierre Bédos
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

View more
  1 in total

1.  Structure of a lipopolysaccharide regulator reveals a road to new antibiotics.

Authors:  Russell E Bishop
Journal:  Nature       Date:  2020-08       Impact factor: 49.962

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.